Build high-quality atrial fibrillation models in 7 days.
The development of chamber specific axoCells atrial cardiomyocytes from iPSCs offers the potential for disease models of atrial fibrillation to be established which may provide information on therapeutics that modify the phenotypic markers of cardiovascular disease and atrial fibrillation. Derived from consenting donor fibroblasts, our atrial cardiomyocytes have been specifically developed for use in drug validation and cardiotoxicity screening.
axoCells atrial cardiomyocytes represent a highly validated, physiologically relevant model and have been extensively characterized structurally, functionally and morphologically. Protein and gene expression, beat rate and action potential parameters, along with functionality of the core cardiac and atrial-specific ion channels have been reported. Molecular characterization of axoCells atrial cardiomyocytes reveals the expression of cardiac and atrial-specific markers troponin T, atrial myosin light chain 2 (MLC2a) and atrial natriuretic peptide (ANP) and key ion channels, Kv1.5 and Kir3.1/3.4. Functionally, axoCells atrial cardiomyocytes elicit spontaneous action potentials, express functional core cardiac ion channels, INa, ICa,L and IKr and exhibit a steady beat rate.
Supporting quality and consistency
Confidently carry out your workflow with iPSCs manufactured in our ISO:9001-accredited production facility, guided by our rigorous quality control procedures and decades of scientific experience. All cells come with a full Certificate of Analysis and are officially certified by HPSCreg®, to ensure ethical and biological conformity for your peace of mind.
Join our customer base of top ten biopharma and academic institutions in building robust, physiologically relevant disease models for research and drug discovery.
How to get highly functional axoCells Atrial Cardiomyocytes
- You’ll need atrial Cardiomyocytes ax2518, cardiomyocyte maintenance media and fibronectin.
- Follow the protocol for use on cell culture plates.
- 7 days later you will have highly functional atrial cardiomyocytes
*Additional third party components are required. Be sure to check the protocol before you start using the atrial cardiomyocyte kit.
axoCells Atrial Cardiomyocytes
|Donor gender||Donor age||Source||Condition||Product code||Cells/vials|
|Male||74 yr||Fibroblasts||Healthy||ax2518||1 million|
Need a quote for this single product or for the whole cell + media + reagent kit? We’re here to help! Click the ‘get a quote’ button or send an email to firstname.lastname@example.org
- Exhibit atrial phenotypes to known selective modulators of atrial-specific currents and known targets of atrial fibrillation
- Show no evidence of endogenous arrhythmias
- Accelerate workflow with cells that spontaneously beat 3 days post-thaw and are assay ready in just 7 days
- Ensure confidence with high-quality cells manufactured in our ISO:9001-accredited production facility under rigorous quality control procedures
Atrial fibrillation is one of the most common arrhythmias to affect the heart and hence there is a a need to develop drugs to target atrial arrhythmia. Current animal models fail to translate in vitro due to fundamental differences in the electrophysiology of cardiac action potentials but human iPSC derived atrial cardiomyocytes offer a more human relevant tool to investigate human atrial fibrillation. Axol’s atrial cardiomyocytes have been extensively characterized and exhibit no endogenous arrhythmias, making them ideal models to test fibrillation candidates.
Protocols for culture of atrial cardiomyocytes in MEA and tissue culture plates for imaging are available.
We maintain or exceed industry-level quality with our ISO:9001-accredited production facility, guided by our rigorous quality control procedures and decades of scientific experience.
All cells come with a full Certificate of Analysis and are officially certified by HPSCreg®, to ensure ethical and biological conformity for your peace of mind.
Licenses & Consent
Axol has obtained all relevant licenses for reprogramming donor samples into iPSCs and differentiating these into atrial cardiomyocytes for commercial use.
Patient samples used to create these cells have been ethically sourced and consented for research and commercial use. All cells come with a full Certificate of Analysis and are officially certified by HPSCreg®, to ensure ethical and biological conformity for your peace of mind.